TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8960901

Group type: EXPERIMENTAL
Intervention: AVP 0.26 microgram/kg body weight i.v.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 2015147

Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine alone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with adrenaline
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with fentanyl
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with adrenaline and fentanyl
Number of subjects: 4
Study: 6613714

Group type: EXPERIMENTAL
Intervention: Alcohol intervention in Experiment 1 (n = 24)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol intervention in Experiment 2 (n = 40)
Number of subjects: 64
Study: 30822290

Group type: EXPERIMENTAL
Intervention: Endurance and resistance training exercise (ERTE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 28771064

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU of cholecalciferol every two weeks for 11-12 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 27044968

Group type: EXPERIMENTAL
Intervention: Summarized cost information
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Quality stars displayed adjacent to cost information
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Understanding of quality stars
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Highlighting high-value plans with a check mark or blue ribbon
Number of subjects: 1025
Study: 24703685

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) for both femur and tibia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Extramedullary guide for tibia and intramedullary guide for femur
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intramedullary guides for both femur and tibia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical axis within ±3° of neutral
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical axis outside ±3° of neutral
Number of subjects: 107
Study: 22365936

Group type: EXPERIMENTAL
Intervention: Tailored newsletter
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard newsletter
Number of subjects: 225
Study: 20031608

Group type: EXPERIMENTAL
Intervention: Verapamil SR treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil treatment
Number of subjects: 0
Study: 17257175

Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg i.v.
Number of subjects: 179

Group type: COMPARATOR
Intervention: dexamethasone 4 mg i.v.
Number of subjects: 179

Group type: COMPARATOR
Intervention: betamethasone 12 mg i.m.
Number of subjects: 179
Study: 18080351

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000
Number of subjects: 360

Group type: COMPARATOR
Intervention: Matched placebo gel
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 or matched placebo gel
Number of subjects: 360
Study: 15016290

Group type: EXPERIMENTAL
Intervention: Observation-only A trials followed by B location search
Number of subjects: 0
Study: 11269542

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 279
Study: 9382514

Group type: EXPERIMENTAL
Intervention: Combination therapy of 5-FU, epirubicin and MMC (FEM group: n=7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Other antineoplastic agents (non-FEM group: n=10)
Number of subjects: 17
Study: 8439641

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 2875907

Group type: EXPERIMENTAL
Intervention: Temelastine 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temelastine 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temelastine 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorpheniramine 4 mg (Control)
Number of subjects: 12
Study: 31025804

Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 64

Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 64
Study: 28750067

Group type: EXPERIMENTAL
Intervention: Regular county council workshop training followed by six sessions of supervision
Number of subjects: 174

Group type: COMPARATOR
Intervention: Regular county council workshop training
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups (workshop training and supervision)
Number of subjects: 174
Study: 25851642

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Performance testing
Number of subjects: 31
Study: 24072969

Group type: EXPERIMENTAL
Intervention: Muscle force training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Balance and muscle force training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self-administered training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Guided training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 55
Study: 20950307

Group type: EXPERIMENTAL
Intervention: Conveen Optima urisheaths
Number of subjects: 61

Group type: COMPARATOR
Intervention: Absorbent products (APs)
Number of subjects: 61
Study: 19263014

Group type: EXPERIMENTAL
Intervention: OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day
Number of subjects: 160

Group type: COMPARATOR
Intervention: OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day
Number of subjects: 160
Study: 17245477

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15044693

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (As(2)O(3))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of ATRA and As(2)O(3)
Number of subjects: 61
Study: 11437721

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 9724825

Group type: EXPERIMENTAL
Intervention: Nutrition program assessments and interventions during baseline
Number of subjects: 49
Study: 8304833

Group type: EXPERIMENTAL
Intervention: rPDGF‐BB 100 micrograms/mL
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: rPDGF‐BB 300 micrograms/mL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3059275

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotherapy with ceftriaxone (CRO)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non prophylactic CRO
Number of subjects: 78
Study: 30535165

Group type: EXPERIMENTAL
Intervention: 2-mA anodal tDCS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 28750995

Group type: EXPERIMENTAL
Intervention: Stretching of piriformis and iliopsoas muscles
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stretching of piriformis and iliopsoas muscles and Maitland's rhythmic oscillatory thoracic mobilization
Number of subjects: 48

Group type: COMPARATOR
Intervention: Seat cushioning + Sitz bath + Phonophorosis
Number of subjects: 48
Study: 26607432

Group type: EXPERIMENTAL
Intervention: OSTA program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 320
Study: 23462284

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT/A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 21252669

Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 0
Study: 19323021

Group type: EXPERIMENTAL
Intervention: Xylitol gum containing funoran and calcium hydrogenphosphate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Xylitol gum
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sugar gum
Number of subjects: 7

Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 7
Study: 16991062

Group type: EXPERIMENTAL
Intervention: Bilateral sequential total knee arthroplasty under one anaesthesia session
Number of subjects: 140
Study: 15152279

Group type: EXPERIMENTAL
Intervention: Somatostatin (6000 IU/day intravenously)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg three times daily subcutaneously)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (standard medical treatment)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 11425674

Group type: EXPERIMENTAL
Intervention: Fluorescein dye prewarmed to body temperature
Number of subjects: 394

Group type: COMPARATOR
Intervention: Fluorescein dye at room temperature (control group)
Number of subjects: 394
Study: 9274455

Group type: EXPERIMENTAL
Intervention: i.v. 5-dFUR 3000 mg/m2 with L-leucovorin 25 mg/dose on days 1-5, every 3 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: oral 5-dFUR 1200 mg/m2 for 5 days followed by 5 days off with oral L-leucovorin 25 mg/dose 2 h before 5-dFUR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48

Group type: COMPARATOR
Intervention: oral 5-dFUR
Number of subjects: 48

Group type: COMPARATOR
Intervention: i.v. 5-dFUR
Number of subjects: 48
Study: 8101695

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 0
Study: 3729450

Group type: EXPERIMENTAL
Intervention: LENTINAN in patients with normal protein levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: LENTINAN in patients with low protein levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OK-432 or LENTINAN in N-mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: OK-432 or LENTINAN in D-mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol administration every 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy in N-mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of OK-432 or LENTINAN
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-mice
Number of subjects: 0
Study: 30406696

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17938 (1×10^8 cfu) for 28 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 59
Study: 28441936

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BI) determination of normally hydrated weight to set a post-dialysis target weight that limits volume depletion
Number of subjects: 516

Group type: COMPARATOR
Intervention: Current standard practice (control group)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 516
Study: 25381018

Group type: EXPERIMENTAL
Intervention: 5% Carbamide Plus
Number of subjects: 33

Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 33
Study: 24278177

Group type: EXPERIMENTAL
Intervention: Formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses
Number of subjects: 60
Study: 21068104

Group type: EXPERIMENTAL
Intervention: Discontinuation of the last disease-modifying antirheumatic drug (DMARD) after achieving DAS < 1.6 for ≥ 6 months.
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Restarting treatment with DMARD after DAS increased to ≥ 1.6.
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Patients who restarted treatment during the year of DAS increase.
Number of subjects: 508
Study: 18467929

Group type: EXPERIMENTAL
Intervention: Experimental computerized training for visual-motor coordination
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 1
Study: 17080541

Group type: EXPERIMENTAL
Intervention: Baduanjin qigong training program for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 12964891

Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramipexole and Ropinirole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabergoline, Pramipexole, Ropinirole
Number of subjects: 0
Study: 11121628

Group type: COMPARATOR
Intervention: Conventional radiotherapy (Arm I, n = 82)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Conventional/accelerated‐hyperfractionated radiotherapy (Arm II, n = 77)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Conventional/accelerated‐hyperfractionated radiotherapy (Arm II)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional radiotherapy (Arm I)
Number of subjects: 159
Study: 9226387

Group type: EXPERIMENTAL
Intervention: Tetracycline fibers (Actisite) applied to 2 selected lesions in 9 patients (LT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Polymeric tetracycline HCl containing fibers applied after full mouth scaling and root planing in 10 patients (FT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Full mouth scaling and root planing with 0.2% chlorhexidine rinse in 10 patients (FT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 19
Study: 8428895

Group type: EXPERIMENTAL
Intervention: quazepam 15 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: triazolam 0.5 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study: 3304301

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 10 micrograms/kg body weight intravenously
Number of subjects: 10
Study: 29128895

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 756

Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 756
Study: 28882116

Group type: EXPERIMENTAL
Intervention: PROMPT training package (Train the Trainers program) implemented in participating Units
Number of subjects: 12
Study: 25687748

Group type: EXPERIMENTAL
Intervention: Robotically assisted navigation (Hansen Sensei(®) X)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard navigation
Number of subjects: 40
Study: 23991629

Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CSII with rosiglitazone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CSII with metformin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CSII with α-lipoic acid
Number of subjects: 160
Study: 21146914

Group type: EXPERIMENTAL
Intervention: HeartCode BLS System
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BLS Anytime
Number of subjects: 180

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 180
Study: 18197742

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 16511428

Group type: EXPERIMENTAL
Intervention: DNA prime, recombinant fowlpox virus boost vaccine (1 mg pHIS-HIV-B at weeks 0 and 4, 5 x 10^7 pfu rFPV-HIV-B at week 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12687838

Group type: EXPERIMENTAL
Intervention: Patients with atrial flutter (group I)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Patients with atrial fibrillation (group II)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of group II to group I
Number of subjects: 201
Study: 12846617

Group type: EXPERIMENTAL
Intervention: Intra-operative end tidal PCO2 of 5.99 kPa (hypercapnia)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-operative end tidal PCO2 of 3.99 kPa (control)
Number of subjects: 20
Study: 10474500

Group type: EXPERIMENTAL
Intervention: Multileaf collimator (MLC) supported by a digitizing data entry system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional shielding with geometrically shaped blocks
Number of subjects: 66
Study: 8768868

Group type: EXPERIMENTAL
Intervention: CPA‐100 (100 mg/day) + TE (100 mg/week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPA‐50 (50 mg/day) + TE (100 mg/week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: TE (100 mg/week) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPA‐100 and CPA‐50 groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study: 1881954

Group type: EXPERIMENTAL
Intervention: Pulsed electrical stimulation (30 minutes, twice daily, pulse frequency of 128 pps, peak amplitude of 29.2 mA) for chronic dermal ulcers.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham electrical stimulation (same protocol as treatment group).
Number of subjects: 47
Study: 6189601

Group type: EXPERIMENTAL
Intervention: Peplomycin plus carbazilquinone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Peplomycin plus mitomycin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 53
Study: 3106459

Group type: EXPERIMENTAL
Intervention: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0 plus TRH (6 micrograms/min) infusion between ‐30 and +120 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: TRH (6 micrograms/min) infusion between ‐30 and +120 min
Number of subjects: 9
Study: 31665956

Group type: EXPERIMENTAL
Intervention: Individualized hemodialysis scheme (low temperature, pattern of natrium, pattern of step ultrafiltration, dialysate containing glucose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dialysis model
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualized hemodialysis scheme
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups after dialysis
Number of subjects: 60
Study: 30279333

Group type: EXPERIMENTAL
Intervention: Whole milk supplementation (250 mL/day for four weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Whole milk supplementation
Number of subjects: 62
Study: 26689520

Group type: EXPERIMENTAL
Intervention: Peritubal analgesic infiltration with 10mL of bupivacaine
Number of subjects: 105
Study: 24025464

Group type: EXPERIMENTAL
Intervention: Caring∼Web site intervention for family caregivers of stroke patients
Number of subjects: 36
Study: 22025430

Group type: EXPERIMENTAL
Intervention: COMPETE III CDSS intervention
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1102
Study: 18471347

Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet after a high-fat meal
Number of subjects: 23
Study: 16926667

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16) participated in a supervised exercise programme for 8 months consisting of two sessions of circuit weight training and two sessions of aerobic training.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 16) after 3 months of detraining
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 30
Study: 14693322

Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 10686266

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 90% power of the motor threshold, stimulation frequency of 10 Hz for either 2 sec or 6 sec for 20 trains, treated for up to 20 treatment days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) performed according to standard protocols.
Number of subjects: 40
Study: 9077613

Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid at 39 degrees C
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ambient temperature irrigation fluid
Number of subjects: 35
Study: 8336746

Group type: EXPERIMENTAL
Intervention: Combined out‐patient therapy program (physical exercise, dietary counseling, psychological support)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (initial dietary instruction only)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (program and control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Program children only
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Program children
Number of subjects: 17
Study: 3511478

Group type: EXPERIMENTAL
Intervention: True ultrasound (US) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham ultrasound (US) therapy
Number of subjects: 20
Study: 31865815

Group type: EXPERIMENTAL
Intervention: Intradermal injection of botulinum toxin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 20
Study: 31721257

Group type: EXPERIMENTAL
Intervention: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29648856

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CGT + Citalopram (CGT + CIT)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CGT + Placebo (CGT + PBO)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Working alliance
Number of subjects: 202
Study: 26541641

Group type: EXPERIMENTAL
Intervention: Harmonic® with Tisseel® fibrin glue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Harmonic® only
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 20
Study: 23294276

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197